Global Alzheimer's trial will study Roche, Lilly drugs

10/10/2012 | Reuters

Experimental Alzheimer's drugs from Roche Holding and Eli Lilly and Co. will be studied in a global trial of 160 patients with genetic indicators that they are prone to the disease. The study, set to begin next year, will include Roche's gantenerumab and Lilly's solanezumab, and a beta-secretase inhibitor from Lilly could be added.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD